Parkman Healthcare Partners LLC Cullinan Oncology, Inc. Transaction History

Parkman Healthcare Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $3.57 Million - $6.69 Million	-351,481 Reduced 66.33%	178,396 $3.04 Million
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $719,031 - $932,280	91,132 Added 20.77%	529,877 $5.4 Million
Q3 2023 Nov 14, 2023	BUY	$9.05 - $11.72 $832,274 - $1.08 Million	91,964 Added 26.52%	438,745 $3.97 Million
Q2 2023 Aug 11, 2023	BUY	$8.8 - $13.4 $1.56 Million - $2.37 Million	176,895 Added 104.13%	346,781 $3.73 Million
Q1 2023 May 12, 2023	BUY	$10.2 - $11.91 $392,781 - $458,630	38,508 Added 29.31%	169,886 $1.74 Million
Q4 2022 Feb 13, 2023	BUY	$9.72 - $13.62 $1.28 Million - $1.79 Million	131,378 New	131,378 $1.39 Million

146

67.6M

612K

118K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $499M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.